Dr. Fang Xie is an Instructor in Medicine at Beth Israel Deaconess Medical Center (BIDMC) and Harvard Medical School, where he specializes in translational cancer research. After earning his PhD in Genetics from Fudan University, he completed fellowships at the Mayo Clinic and subsequently joined the Balk Lab at BIDMC in 2017. His background combines deep expertise in molecular genetics with advanced therapeutic development.
Dr. Xie's scientific interests are primarily focused on the molecular mechanisms of therapeutic resistance in advanced prostate cancer, specifically metastatic castration-resistant prostate cancer (CRPC). His research involves using 3D cell culture and patient-derived organoid models to mimic in vivo environments and identify novel drug combinations that can overcome resistance to treatments like taxane-based chemotherapy. Additionally, he is active in the broader life sciences community, serving as a leader within the Harvard Biotech Club and the Boston Chapter of Nucleate, reflecting an interest in the intersection of academic research and entrepreneurial biotechnology.